EDIT BULLISH

٤ أكتوبر ٢٠٢٤

Editas Medicine (NASDAQ: EDIT) is focused on developing CRISPR-based gene-editing technologies and has a solid pipeline for treating various genetic diseases, cancers, and autoimmune conditions. They've partnered with major players like Bristol Myers Squibb and Vertex Pharmaceuticals, boosting their credibility in the field. Editas also holds a strong patent portfolio, including exclusive licenses to key CRISPR patents from the Broad Institute and Harvard, which strengthens their ability to develop new treatments. Despite being somewhat overlooked compared to competitors like CRISPR Therapeutics, with a market cap of $461 million, EDIT has significant upside potential, targeting $7.40 and $11.60.